Merck & Co., Inc. (MRK): A Bull Case Theory

We came crossed a bullish thesis connected Merck & Co., Inc. connected R. Dennis’s Substack’s Substack by OppCost. In this article, we volition summarize the bulls’ thesis connected MRK. Merck & Co., Inc.'s stock was trading astatine $106.90 arsenic of January 28th. MRK’s trailing and guardant P/E were 14.28 and 17.27 respectively according to Yahoo Finance.

Copyright: zneb076 / 123RF Stock Photo

Merck & Co., Inc. operates arsenic a healthcare institution worldwide. MRK has emerged arsenic the absorption of a high-conviction bullish thesis pursuing the detection of an unusually ample organization options commercialized connected December 8, 2025, erstwhile a blase marketplace subordinate purchased 30,000 April 17, 2026 $110 telephone contracts, representing astir $300 cardinal successful notional exposure. This trade, executed arsenic MRK retraced precisely to its 21-day exponential moving average, signals a deliberate and well-timed stake connected a medium-term repricing alternatively than a short-term speculative move.

The prime of the April 2026 expiration aligns with aggregate anticipated catalysts, including FY2025 earnings, aboriginal 2026 pipeline updates, and expanding visibility into Merck’s post-Keytruda maturation trajectory. To optimize superior efficiency, the thesis proposes a split-strike hazard reversal, selling April $85 puts to concern the $110 calls, anchoring downside hazard to the 200-day elemental moving average, a level wide viewed arsenic a structural accumulation portion for a high-quality antiaircraft sanction similar Merck.

Fundamentally, assurance is underpinned by the accelerating motorboat of Winrevair, which is already tracking toward blockbuster status, the continued durability and lifecycle hold of the Keytruda franchise, and a deepening pipeline that includes promising assets successful cardiology, vaccines, and respiratory disease.

These drivers coincide with a broader macro rotation into healthcare defensives, wherever Merck trades astatine a valuation discount portion offering a beardown dividend output that reinforces a downside floor. Even absent aggregate expansion, the operation offers constricted downside with uncapped upside, portion a palmy cardinal rerating could propel MRK good beyond the $110 strike, delivering an asymmetric and compelling risk/reward profile.

Previously, we covered a bullish thesis on Merck & Co., Inc. (MRK) by Charly AI successful April 2025, which highlighted improving margins, beardown escaped currency travel generation, and durable maturation from oncology and cardiovascular franchises. MRK’s banal terms has appreciated by astir 30.50% since our coverage owed to net momentum and pipeline execution. OppCost shares a akin presumption but emphasizes organization options enactment and method positioning.